[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-rheumatism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-rheumatism":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,73,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100603103","justification-of-the-initial-diagnosis-and-evaluation-of-the-overall-evolution-of-a-cohort-of-recent-polymyalgia-rheumatica-jadore-100603103",false,"NCT07132164","Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE)","Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica","JADORE","Inclusion Criteria:\n\n* Age greater than or equal to 50, with no upper age limit\n* Inflammatory shoulder +\u002F- hip pain\n* Abnormal CRP (≥10mg\u002FL)\n* Patients for whom the referring rheumatologist accepts the diagnosis of PPR after carrying out the assessment corresponding to his or her current practice\n* Patients for whom the referring rheumatologist has indicated that corticosteroid therapy should be started in the strict context of PPR or as background treatment for PPR.\n* Symptoms have progressed for 24 weeks or less\n\nExclusion Criteria:\n\n* Presence, at the time of diagnosis, of symptoms and\u002For signs suggesting a diagnosis of associated giant cell arteritis\n* Immuno-induced PPR\n* Patients receiving immunosuppressive treatment with methotrexate or immunotherapy targeting interleukin-6 at inclusion.\n* Patients who have received corticosteroid therapy for more than 30 days or a cumulative dose of more than 500 mg of Prednisone equivalent in the month preceding the screening visit.\n* Patients with another chronic condition requiring long-term corticosteroid therapy or repeated courses of corticosteroids.\n* Patients not affiliated to a social security scheme\n* Patients unable to consent or unable or unwilling to complete their corticosteroid dose monitoring record.\n* Pregnancy\n* Patients under guardianship, curatorship or safeguard of justice","ALL","50 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","Pseudo-rheumatoid arthritis (PRA) is a common inflammatory rheumatic disease of the elderly, characterized by inflammatory shoulder and\u002For hip pain. Its routine diagnosis is based on a number of clinical criteria, the presence of a biological inflammatory syndrome and the elimination of the main differential diagnoses. It is sometimes referred to as PPR syndrome, since around 25% of initial diagnoses are not confirmed at one year's follow-up (PPR syndrome revealing rheumatoid arthritis, microcrystalline rheumatism, etc.). Diagnosis may be facilitated by ultrasound scans of the shoulders and hips, which may show characteristic inflammatory lesions, or by PET scans when there is a marked deterioration in general condition or other clinical atypia. PPR may be associated at the outset, or it may evolve into the rarer vasculitis of the elderly, giant cell arteritis (GCA), a condition that can lead to severe and irreversible neurological vascular damage if not treated early.\n\nProlonged, moderate-dose corticosteroid therapy is the cornerstone of PPR treatment, although new treatments are in the process of obtaining marketing authorization to enable cortisone sparing. Anti-IL-6 agents, and in particular Tocilizumab, have demonstrated their efficacy in recent cortico-dependent PPR, Sarilumab has obtained marketing authorization for cortico-dependent PPR in the USA in 2023, and other therapeutic classes are currently being evaluated in this situation. Recommendations, including those of ACR\u002FEULAR in 2015, advise a strategy of initiating corticosteroid therapy at a moderate dose, with a dosage of between 12.5 and 25 mg prednisone equivalent per day, and gradually tapering off with the aim of reaching a dosage of 10 mg prednisone equivalent per day at week 8, to achieve complete weaning at 12 months. However, on the one hand, these recommendations are not based on clinical trials and, on the other, the main comorbidities associated with PPR are related to this long-term corticosteroid therapy. Lastly, we know that around 50% of patients do not follow this tapering-off protocol, with either relapses (estimated at 50% during tapering) or the impossibility for around 25% of patients to stop corticosteroid therapy. However, there are currently no predictive factors for the evolution of PPR.\n\nPPR activity can be measured either using a validated score, the DAS-PPR, or according to the opinion of the rheumatologist. Good progression of rheumatoid arthritis is characterized by a low activity score (DAS-PPR\\\u003C10) and, wherever possible, discontinuation of treatment within one year, as recommended by international experts.\n\nThe main objective of this cohort is therefore to evaluate the percentage of patients with low-activity PPR (DAS-PPR\\\u003C10) and no treatment at 12 months.\n\nSecondary objectives will concern the initial phenotypic and evolutionary description of PPR (complete initial phenotypic characteristics, including some exploratory ones (imaging, biology, immunology, genetics, microbiota, avatars). The evolution of the disease, with the percentage of relapses during the decline or distant relapses, percentage of association with ACG, mortality rate, as well as the prognostic factors of these different evolutionary forms. A description of the disease-modifying treatments used (corticosteroid therapy and its decline, other immunomodulators), as well as a record of the complications presented by patients (development of ACG, corticosteroid toxicity, sarcopenia, osteoporosis fractures, diverticular perforation). Finally, many pathologies can clinically and biologically mimic PPR, leading to erroneous prescriptions of glucocorticoids for prolonged periods, and sometimes a delay in the diagnosis of serious conditions. These classic differential diagnoses will be investigated according to the clinical context and the clinician's judgement, and the diagnostic value of tests such as joint ultrasound, PET scans and biomarkers can be assessed.\n\nWith regard to patient follow-up, if an alternative diagnosis is identified immediately after the completion of additional examinations, the patient is no longer followed up in the study, and the alternative diagnosis is noted by the investigator. For patients for whom the investigator's conviction concerning the diagnosis of PPR remains above 50%, as at inclusion, follow-up in the study is continued. At one year's follow-up, if an alternative diagnosis has been made, this is collected and the patient is no longer followed up in the cohort. Follow-up for other patients then continues for 5 years. Deterministic matching to the SNDS will be performed for each patient included.\n\nTo date, there is no French prospective cohort dedicated to the follow-up of patients with a recent form of PPR, as has been done for rheumatoid arthritis, spondyloarthritis and psoriatic arthritis. The creation of such a cohort will improve our knowledge of this pathology, in terms of both pathophysiology and routine management.",[25,26],"Polymyalgia Rheumatica","Inflammatory Rheumatism",[28],"polymyalgia Rheumatica","NOT_YET_RECRUITING","2026-06-05",{"date":32,"type":33},"2026-06-08","ACTUAL",{"date":35,"type":21},"2026-07-01",{"date":37,"type":21},"2035-07-01",{"name":39,"class":40},"University Hospital, Brest","OTHER",30,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100546511","dynamics-in-bone-turnover-markers-during-and-after-short-term-glucocorticoid-treatment-in-patients-with-an-inflammatory-joint-disease-100546511","NCT06395883","Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease","Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease - the BOOGIE Study","BOOGIE","Inclusion Criteria:\n\n* diagnosis of inflammatory rheumatic joint disease\n* indication of disease modifying treatment initiation with or without glucocorticoids OR\n* stable DMARD treatment with parenteral glucocorticoid injection\n\nExclusion Criteria:\n\n* known osteoporosis or osteoporosis treatment\n* women during the transitory phase\n* oestrogen treatment\n* any fracture within the last year\n* chronic glucocorticoid treatment\n* glucocorticoid treatment within the last year prior to inclusion\n* active cancer\n* kidney failure","25 Years","90 Years",{"count":53,"type":21},160,"Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment.\n\nThere is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.",[56,57,26],"Osteoporosis","Osteoporosis, Steroid Induced",[59,60,61],"Bone turnover","Bone turnover markers","Glucocorticoids","RECRUITING","2025-08-19",{"date":65,"type":33},"2025-08-24",{"date":67,"type":33},"2025-01-01",{"date":69,"type":21},"2028-12",{"name":71,"class":40},"Diakonhjemmet Hospital",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100264255","glucocorticoid-induced-osteoporosis-in-patients-with-chronic-inflammatory-rheumatic-diseases-or-psoriasis-100264255","NCT02719314","Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis","Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids","Rh-GIOP","Inclusion Criteria:\n\nEvery patient has to fulfill the following inclusion criteria:\n\n* patients with (control group: without) a diagnosis of a chronic inflammatory rheumatic disease or psoriasis\n* patients who (not for control groups) have\u002Fhad already a glucocorticoid therapy, or patients in which the implementation of a new long-term GC therapy is expected\n* patients who, according to the Dachverband Osteologie (DVO, Germany) guidelines, attend our osteoporosis and bone metabolism outpatient consultation hours or are referred by the hospital wards of the Charité for diagnosis, treatment or follow-up\n* capability to understand the patient information\n* consent to participation in the project and storage of data\n\nExclusion Criteria:\n\nIf any of the following exclusion criteria is true, the patient must not be included in this study:\n\n* alcohol, medication and\u002For drug addiction\n* severe psychiatric diseases limiting the comprehension of the project plan and the study protocol (persons incapable of giving informed consent)\n* pregnant and lactating patients\n* patients incapable of giving informed consent for any reason\n* prisoners and all persons who are committed to an institution due to an official or judicial order","18 Years",{"count":83,"type":21},10000,"14 Years","Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time. The available data describing frequency and severity of these adverse effects are fragmentary. This statement is especially true for glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases or (in part) psoriasis(arthritis). The state of knowledge and scientific data, being sparse, is partly conflicting and often derived from over-aged projects or studies. Therefore, there are urgent needs to work on various current questions systematically and at the highest scientific level possible. In order to address these needs, we aim at collecting and analyzing disease- and bone-related data from patients with chronic inflammatory rheumatic diseases or psoriasis and therapy with glucocorticoids, and to build a respective GIOP-Databank. Patients will attend for diagnostics, and where necessary therapy and follow-up of GIOP, according to current guidelines. Clinical, laboratory and instrumental examination results from more than 1000 patients in the first three years of the project are planned to be documented in a prospective database.",[56,26],"2025-02-11",{"date":89,"type":33},"2025-02-13",{"date":91,"type":33},"2015-12",{"date":93,"type":21},"2029-07",{"name":95,"class":40},"Prof Dr Frank Buttgereit",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":96},"100558994","diagnostic-performance-of-18-fdg-pet-ct-scores-for-the-diagnosis-of-polymyalgia-rheumatica-100558994","NCT06558357","Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica","Evaluation of the Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica and Comparison With Others Inflammatory Rheumatic Diseases.","RHUMATEP","Inclusion Criteria:\n\n* Having 18-FDG PET-CT between 2012 and 2024\n* Diagnosis of inflammatory rheumatism by specialist doctor\n* Adult without opposition to use there data for research\n* Affiliate to social security system\n\nExclusion Criteria:\n\n* Refusal participation\n* Patient under juridic protection","110 Years",{"count":107,"type":21},210,"Study of the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and comparaison with others inflammatories diseases.",[26,110,111],"18-FDG","Positron-emission Tomography",[113,114,115,116,117],"Polymyalgia rheumatica","FDG","PET","Diagnostic performance","score","2024-08-19",{"date":120,"type":33},"2024-08-20",{"date":122,"type":21},"2024-09-01",{"date":124,"type":21},"2024-12-31",{"name":39,"class":40}]